Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC

Forefront Analytics LLC raised its holdings in Athira Pharma, Inc. (NASDAQ:ATHA) by 126.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,595 shares of the company’s stock after purchasing an additional 25,979 shares during the quarter. Forefront Analytics LLC owned about 0.12% of Athira Pharma worth $123,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. increased its stake in shares of Athira Pharma by 84.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock worth $1,363,000 after acquiring an additional 227,278 shares during the period. Perceptive Advisors LLC grew its stake in shares of Athira Pharma by 12.6% during the 4th quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock worth $13,129,000 after purchasing an additional 605,686 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Athira Pharma by 281.5% in the 1st quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock valued at $1,505,000 after purchasing an additional 405,793 shares in the last quarter. Mirador Capital Partners LP acquired a new stake in shares of Athira Pharma in the first quarter valued at about $57,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Athira Pharma by 25.5% in the second quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after purchasing an additional 111,759 shares during the period. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ATHA shares. Rodman & Renshaw cut Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. BTIG Research downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Mizuho cut Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $5.00 to $0.50 in a research report on Thursday, September 19th. Finally, JMP Securities lowered shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th.

Athira Pharma Stock Up 6.1 %

Athira Pharma stock opened at $0.44 on Friday. Athira Pharma, Inc. has a 52 week low of $0.41 and a 52 week high of $4.30. The firm has a market capitalization of $17.08 million, a PE ratio of -0.15 and a beta of 2.90. The firm’s 50-day simple moving average is $2.21 and its 200 day simple moving average is $2.39.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.05. On average, research analysts expect that Athira Pharma, Inc. will post -2.57 EPS for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.